stockrow
Saturday 7 November 2026
Export DTIL’s income statement to Excel — free account
Precision BioSciences, Inc.
DTIL Healthcare Biotechnology
Precision BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $34.3 million, down 50.1% from fiscal 2024.
- Revenue
- +37,272.4%
- EPS
- +85.0%
- Free cash flow
- −0.52%
- Total debt
- +0.22%
Quarter to September 2026, against a year earlier
10.75
0.88
+8.92%
Follow DTIL
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | — | — |
P/S ratio |
1.56 | 3.01 | — | — | |
P/FCF ratio |
0.00 | 0.00 | — | — | |
P/Operating CF |
(4.74) | (11.35) | — | — | |
P/B ratio |
0.58 | 1.78 | — | — | |
Price to Tangible BV |
0.59 | 1.81 | — | — | |
EV/Sales |
(1.16) | 1.26 | — | — | |
EV/EBITDA |
0.80 | 0.00 | — | — | |
EV/Operating CF |
0.60 | (0.97) | — | — | |
EV/FCF |
0.60 | (0.96) | — | — | |
Quick Ratio |
12.97 | 13.56 | 12.26 | 9.90 | |
Current Ratio |
13.32 | 14.02 | 12.82 | 10.47 | |
Net Debt/EBITDA |
(7.07) | 9.34 | 3.51 | 2.99 | |
Debt/Assets |
14.51% | 15.58% | 17.81% | 18.63% | |
Debt/Equity |
0.24 | 0.29 | 0.50 | 0.43 | |
Asset Turnover |
0.24 | 0.34 | 0.00 | 0.00 | |
Operating CF/Net income |
(0.56) | 0.65 | 0.41 | 1.99 | |
Capex/Depreciation |
(0.48) | (0.18) | 0.00 | (0.34) | |
Interest Coverage |
35.94 | (29.18) | (63.87) | (66.54) | |
Research and Development Expense of Revenue |
42.29% | 120.96% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
21.14% | 62.77% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
5.97% | 14.29% | 0.00% | 0.00% | |
Graham Net Nets |
1.06 | 0.30 | — | — | |
Graham Number |
0.00 | 0.00 | — | — | |
Earnings Yield |
(123.08%) | (66.55%) | — | — | |
Free Cash Flow Yield |
(124.59%) | (43.67%) | — | — | |
Revenue per Share |
2.67 | 0.44 | 0.00 | 0.00 | |
Operating CF per Share |
(0.88) | (0.48) | (0.52) | (0.55) | |
Capex per Share |
(0.03) | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.90) | (0.49) | (0.52) | (0.56) | |
Cash per Share |
9.01 | 4.11 | 3.39 | 2.98 | |
Shareholders Equity per Share |
7.19 | 3.09 | 1.75 | 1.89 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.19 | 3.09 | 1.75 | 1.89 | |
Free Cash Flow |
(11.57) | (12.05) | (13.44) | (15.33) | |
Working Capital |
109.83 | 100.94 | 84.41 | 78.31 | |
Capital Expenditures |
(0.32) | (0.11) | 0.00 | (0.20) | |
Net Current Asset Value |
56.57 | 40.90 | 10.92 | 17.97 | |
EV/EBIT |
0.76 | 0.00 | — | — | |
Capex to Sales |
0.01 | 0.01 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
— | 2.09 | — | — | |
Average Payables |
0.80 | 0.93 | 0.97 | 1.08 | |
Average Assets |
145.40 | 134.15 | 117.42 | 106.94 | |
Average Common Equity |
74.32 | 62.72 | 39.67 | 34.20 |
Columns are period end dates · fundamentals updated 5 Nov 2026